| Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century S Watson, O Caster, PA Rochon, H den Ruijter EClinicalMedicine 17, 100188, 2019 | 214 | 2019 |
| Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase® RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén Drug Safety 40 (1), 81-90, 2017 | 116 | 2017 |
| The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models J Ribbing, J Nyberg, O Caster, EN Jonsson Journal of pharmacokinetics and pharmacodynamics 34 (4), 485-517, 2007 | 107 | 2007 |
| Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank O Caster, K Juhlin, S Watson, GN Norén Drug Safety 37 (8), 617-628, 2014 | 106 | 2014 |
| Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations O Caster, Y Aoki, LM Gattepaille, B Grundmark Drug Safety 43, 479-487, 2020 | 102 | 2020 |
| Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database O Caster, GN Norén, D Madigan, A Bate Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010 | 95 | 2010 |
| Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ... Drug Safety 42, 1393-1407, 2019 | 91 | 2019 |
| Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project O Caster, J Dietrich, ML Kürzinger, M Lerch, S Maskell, GN Norén, ... Drug safety 41, 1355-1369, 2018 | 64 | 2018 |
| Earlier discovery of pregabalin’s dependence potential might have been possible O Caster, IR Edwards, GN Norén, M Lindquist European journal of clinical pharmacology 67 (3), 319-320, 2011 | 50 | 2011 |
| Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance GN Norén, O Caster, K Juhlin, M Lindquist Drug safety 37 (9), 655-659, 2014 | 45 | 2014 |
| vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real‐world use O Caster, L Sandberg, T Bergvall, S Watson, GN Norén Pharmacoepidemiology and Drug Safety 26 (8), 1006-1010, 2017 | 39 | 2017 |
| Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross … I Oosterhuis, H Taavola, PM Tregunno, P Mas, S Gama, V Newbould, ... Drug safety 41, 969-978, 2018 | 38 | 2018 |
| Reporting Patterns Indicative of Adverse Drug Interactions J Strandell, O Caster, A Bate, N Norén, IR Edwards Drug safety 34 (3), 253-266, 2011 | 38 | 2011 |
| The development and evaluation of triage algorithms for early discovery of adverse drug interactions J Strandell, O Caster, J Hopstadius, IR Edwards, GN Norén Drug safety 36 (5), 371-388, 2013 | 36 | 2013 |
| Reflections on attribution and decisions in pharmacovigilance O Caster, IR Edwards Drug safety 33, 805-809, 2010 | 25 | 2010 |
| Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance O Caster, A Conforti, E Viola, IR Edwards European journal of clinical pharmacology 70 (4), 501-503, 2014 | 21 | 2014 |
| Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a … L Rolfes, F van Hunsel, O Caster, H Taavola, K Taxis, E van Puijenbroek British Journal of Clinical Pharmacology 84 (7), 1514-1524, 2018 | 19 | 2018 |
| Logistic regression in signal detection: another piece added to the puzzle. O Caster, GN Norén, D Madigan, A Bate Clinical Pharmacology & Therapeutics 94 (3), 2013 | 19 | 2013 |
| Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome YS Low, O Caster, T Bergvall, D Fourches, X Zang, GN Norén, I Rusyn, ... Journal of the American Medical Informatics Association 23 (5), 968-978, 2016 | 17 | 2016 |
| Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses O Caster, IR Edwards BMC Neurology 15 (1), 206, 2015 | 16 | 2015 |
Niklas NorénChief Science Officer, Uppsala Monitoring Centre, WHO Collaborating Centre for International DrugVerifierad e-postadress på who-umc.org
